Related Experiment Videos
Possible teratogenicity of sulphasalazine
The Medical Journal of Australia
|May 28, 1983
Summary
Sulfasalazine use during pregnancy may be linked to major congenital anomalies in infants. This study suggests potential teratogenic effects, challenging previous assumptions about its safety in expectant mothers with inflammatory bowel disease.
Area of Science:
- Perinatology
- Developmental Toxicology
- Gastroenterology
Background:
- Inflammatory bowel disease (IBD) management during pregnancy presents challenges.
- Sulfasalazine is a common treatment for IBD, but its safety profile in pregnancy requires ongoing evaluation.
Observation:
- Three infants born to mothers treated with sulfasalazine throughout pregnancy exhibited major congenital anomalies.
- These anomalies included cardiac defects (coarctation of the aorta, ventricular septal defect) and severe renal and pulmonary malformations (Potter-type IIa polycystic kidney, absent kidneys, hypoplastic lungs).
Findings:
- The observed congenital anomalies in infants suggest a potential teratogenic effect of sulfasalazine.
- This finding contrasts with some previous reports and warrants further investigation into the drug's developmental toxicity.
Implications:
- Clinicians should carefully consider the risks and benefits of sulfasalazine during pregnancy.
- Further research is crucial to confirm the teratogenicity of sulfasalazine and explore safer alternatives for IBD management in pregnant individuals.